Abstract
Background
Prognosis of appendiceal adenocarcinoma patients is based on burden of disease, histology, and nature of therapy, which remains static despite time in follow-up. We hypothesized that conditional survival provides an informative metric that allows patients better understanding of their disease.
Methods
Using the Surveillance, Epidemiology and End Results database, patients with appendiceal adenocarcinoma from 1988 to 2012 were included. Actuarial Life table analyses and Kaplan–Meier curves were used for statistical inference.
Results
Of 5,952 patients, the median age was 60 years (IQR 50–72) and 52 % were female. Histologies included were adenocarcinoma (NOS 37 %), mucinous adenocarcinoma (MA 53 %), and signet ring cell (SRC 10 %). Five-year overall survival (OS) at diagnosis for patients with metastatic disease was 11 % (NOS), 45 % (MA), and 8 % (SRC), respectively. Annual conditional probability of survival from years 1–5 after diagnosis for patients with SRC with metastatic disease was 55, 60, 68, 55, and 82 % compared with 84, 86, 86, 88, and 92 % with MA. Probability of surviving the first year after extended surgery was 77 % (NOS), 85 % (MA), and 75 % (SRC). Those that survived 5 years after surgery had a 94 % (NOS), 93 % (MA), and 86 % (SRC) probability of surviving the sixth year.
Conclusions
In the setting of dismal cumulative probability of survival (or overall survival), conditional probability is more informative in providing prognostication. This distinction might be important for patients especially with SRC who may live in constant fear of disease. Such data can be used to reassure patients and perhaps modify surveillance strategies for patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Burgess P, Done HJ. Adenocarcinoma of the appendix. J R Soc Med. 1989;82(1):28–9.
Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196–201.
Marudanayagam R, Williams GT, Rees BI. Review of the pathological results of 2660 appendicectomy specimens. J Gastroenterol. 2006;41(8):745–9.
United States Cancer Statistics. 1999–2011 incidence and mortality web-based report.
Cortina R, McCormick J, Kolm P, Perry RR. Management and prognosis of adenocarcinoma of the appendix. Dis Colon Rectum. 1995;38(8):848–52.
Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol. 2012;19(5):1379–85.
Benedix F, Reimer A, Gastinger I, et al. Primary appendiceal carcinoma—epidemiology, surgery and survival: results of a German multi-center study. Eur J Surg Oncol. 2010;36(8):763–71.
Piso P, Bektas H, Werner U, et al. Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol. 2001;27(3):286–90.
Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6(8):727–31.
Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27(8):1089–103.
Nitecki SS, Wolff BG, Schlinkert R, Sarr MG. The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg. 1994;219(1):51–7.
McCusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer. 2002;94(12):3307–12.
Ito H, Osteen RT, Bleday R, Zinner MJ, Ashley SW, Whang EE. Appendiceal adenocarcinoma: long-term outcomes after surgical therapy. Dis Colon Rectum. 2004;47(4):474–80.
Overman MJ, Fournier K, Hu CY, et al. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann Surg. 2013;257(6):1072–8.
McGory ML, Maggard MA, Kang H, O’Connell JB, Ko CY. Malignancies of the appendix: beyond case series reports. Dis Colon Rectum. 2005;48(12):2264–71.
Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36(5):456–62.
Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245(1):104–9.
National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. http://www.seer.cancer.gov.
Gustafsson BI, Siddique L, Chan A, et al. Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy. Int J Oncol. 2008;33(6):1121–31.
Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43.
Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32.
Sugarbaker PH, Zhu BW, Sese GB, Shmookler B. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum. 1993;36(4):323–9.
Chua TC, Pelz JO, Kerscher A, Morris DL, Esquivel J. Critical analysis of 33 patients with peritoneal carcinomatosis secondary to colorectal and appendiceal signet ring cell carcinoma. Ann Surg Oncol. 2009;16(10):2765–70.
H Cho AB Mariotto, LM Schwartz, J Luo, S Woloshin. When Do Changes in Cancer Survival Mean Progress? The Insight From Population Incidence and Mortality. J Natl Cancer Inst Monogr. 2014;49:187–97.
Disclosure
No relevant financial disclosures.
Funding
Lundman Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sekigami, Y., Rajeev, R., Johnston, F. et al. Conditional Survival as a Patient Centered Metric for Patients with Appendiceal Adenocarcinoma. Ann Surg Oncol 23, 2295–2301 (2016). https://doi.org/10.1245/s10434-016-5105-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-016-5105-7